Biotech Values

[genisi]

It has to be the trial cause it's the only one testing combo with Tarceva in NSCLC. Seems likely that MM121 would at least prevent one escape mechanism for tumor growth under the pressure of anti-EGFR therapy, via EGFR/ErbB3 heterodimers. Wonder if overexpression of ErbB3 and/or heregulin in tumors from naive patients could be a biomarker for treatment success with MM121 or perhaps it only develops after resistance to treatment has occurred.